Nuceiva

RSS

botulinum toxin type a

Authorised
This medicine is authorised for use in the European Union.

Overview

Nuceiva is a medicine used to temporarily improve the appearance of vertical frown lines between the eyebrows. It is used in adults less than 65 years of age who have moderate to severe facial lines and in whom those lines are having a significant psychological impact.

Nuceiva contains the active substance botulinum toxin type A.

This EPAR was last updated on 14/10/2019

Authorisation details

Product details
Name
Nuceiva
Agency product number
EMEA/H/C/004587
Active substance
Botulinum toxin type A
International non-proprietary name (INN) or common name
botulinum toxin type a
Therapeutic area (MeSH)
Skin Aging
Anatomical therapeutic chemical (ATC) code
M03AX01
Additional monitoringAdditional monitoring

This medicine is under additional monitoring, meaning that it is monitored even more intensively than other medicines. For more information, see Medicines under additional monitoring.

Publication details
Marketing-authorisation holder
Evolus Pharma Limited
Date of issue of marketing authorisation valid throughout the European Union
27/09/2019
Contact address

70 Sir John Rogerson's Quay
Dublin 2
Ireland

Product information

27/09/2019 Nuceiva - EMEA/H/C/004587 -

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Other muscle relaxants, peripherally acting agents

Therapeutic indication

Temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows seen at maximum frown (glabellar lines), when the severity of the above facial lines has an important psychological impact in adults below 65 years of age.

Assessment history

How useful was this page?

Add your rating